NEW YORK, NY / ACCESSWIRE / August 23, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Koninklijke Philips N.V. (NYSE:PHG)
CONTACT JAKUBOWITZ ABOUT PHG:
https://claimyourloss.com/securities/koninklijke-philips-n-v-loss-submission-form/?id=18847&from=1
Class Period : February 25, 2020 - June 11, 2021
Lead Plaintiff Deadline : October 15, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Philips had deficient product manufacturing controls or procedures; (ii) as a result, the Company's Bi-Level PAP and CPAP devices and mechanical ventilators were manufactured using hazardous materials; (iii) accordingly, the Company's sales revenues from the foregoing products were unsustainable; (iv) the foregoing also subjected the Company to a substantial risk of a product recall, in addition to potential legal and/or regulatory action; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE:ATIP)
CONTACT JAKUBOWITZ ABOUT ATIP:
https://claimyourloss.com/securities/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form/?id=18847&from=1
This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.
Lead Plaintiff Deadline : October 15, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Sesen Bio, Inc. (NASDAQ:SESN)
CONTACT JAKUBOWITZ ABOUT SESN:
https://claimyourloss.com/securities/sesen-bio-inc-loss-submission-form/?id=18847&from=1
Class Period : December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline : October 18, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law